Literature DB >> 19748417

Determination of new cutoff values for indirect immunofluorescence antibody test for Q fever diagnosis in Denmark.

Steen Villumsen1, Charlotte Svaerke Jørgensen, Birgitte Smith, Søren Uldum, Peter Schiellerup, Karen Angeliki Krogfelt.   

Abstract

Q fever is a ubiquitous zoonosis caused by Coxiella burnetii. The disease is emerging in many parts of the world, likely because of increased awareness and availability of better diagnostics. The diagnosis is primarily based on serology. Because the prevalence of the disease varies worldwide, the establishment of local cutoff values is needed. A baseline for antibodies against C. burnetii in Denmark was defined by testing sera from healthy Danish volunteers using a commercially available immunofluorescence antibody test. Cross-reactivity was studied on sera obtained from patients experiencing clinically related diseases. The cutoff titers suggested by the manufacturer were found to result in very low specificity of the test. The specificity was, however, effectively increased by using cutoff titers based on the local baseline and equal to immunoglobulin M (IgM) phase I > or =128, IgM phase II > or =256, IgG phase I > or =512, and IgG phase II > or =1024.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19748417     DOI: 10.1016/j.diagmicrobio.2009.06.004

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  8 in total

1.  No excess risk of adverse pregnancy outcomes among women with serological markers of previous infection with Coxiella burnetii: evidence from the Danish National Birth Cohort.

Authors:  Stine Yde Nielsen; Anne-Marie Nybo Andersen; Kåre Mølbak; Niels Henrik Hjøllund; Bjørn Kantsø; Karen Angeliki Krogfelt; Tine Brink Henriksen
Journal:  BMC Infect Dis       Date:  2013-02-17       Impact factor: 3.090

2.  Antibodies against Coxiella burnetii and pregnancy outcome during the 2007-2008 Q fever outbreaks in The Netherlands.

Authors:  Wim van der Hoek; Jamie C E Meekelenkamp; Alexander C A P Leenders; Nancy Wijers; Daan W Notermans; Chantal W P M Hukkelhoven
Journal:  BMC Infect Dis       Date:  2011-02-11       Impact factor: 3.090

3.  Presence of antibodies against Coxiella burnetii and risk of spontaneous abortion: a nested case-control study.

Authors:  Stine Yde Nielsen; Niels Henrik Hjøllund; Anne-Marie Nybo Andersen; Tine Brink Henriksen; Bjørn Kantsø; Karen Angeliki Krogfelt; Kåre Mølbak
Journal:  PLoS One       Date:  2012-02-21       Impact factor: 3.240

4.  Adverse pregnancy outcomes and Coxiella burnetii antibodies in pregnant women, Denmark.

Authors:  Stine Yde Nielsen; Kåre Mølbak; Tine Brink Henriksen; Karen Angeliki Krogfelt; Carsten Schade Larsen; Steen Villumsen
Journal:  Emerg Infect Dis       Date:  2014-06       Impact factor: 6.883

5.  Absence of convincing evidence of Coxiella burnetii infection in Chile: a cross-sectional serosurvey among healthy adults in four different regions.

Authors:  Thomas Weitzel; Javier López; Gerardo Acosta-Jamett; Sophie Edouard; Philippe Parola; Katia Abarca
Journal:  BMC Infect Dis       Date:  2016-10-06       Impact factor: 3.090

6.  Validation of a Novel Commercial ELISA Test for the Detection of Antibodies against Coxiella burnetii.

Authors:  Salvatore Ledda; Cinzia Santucciu; Valentina Chisu; Giovanna Masala
Journal:  Pathogens       Date:  2020-12-21

7.  National Seroprevalence of Coxiella burnetii in Chile, 2016-2017.

Authors:  Teresa Tapia; María Fernanda Olivares; John Stenos; Rodrigo Iglesias; Nora Díaz; Natalia Vergara; Viviana Sotomayor; Doris Gallegos; Ricardo J Soares Magalhães; Johanna Acevedo; Pamela Araya; Stephen R Graves; Juan Carlos Hormazabal
Journal:  Pathogens       Date:  2021-04-28

8.  Evidence of Q Fever and Rickettsial Disease in Chile.

Authors:  Teresa Tapia; John Stenos; Roberto Flores; Oscar Duery; Rodrigo Iglesias; Maria Fernanda Olivares; Doris Gallegos; Cristian Rosas; Heidi Wood; Johanna Acevedo; Pamela Araya; Stephen R Graves; Juan Carlos Hormazabal
Journal:  Trop Med Infect Dis       Date:  2020-06-11
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.